anti kv 1 3 extracellular antibody (Alomone Labs)


Structured Review

Anti Kv 1 3 Extracellular Antibody, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 93/100, based on 4 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti kv 1 3 extracellular antibody/product/Alomone Labs
Average 93 stars, based on 4 article reviews
Price from $9.99 to $1999.99
Images
1) Product Images from "Localization of Kv1.3 channels in presynaptic terminals of brainstem auditory neurons"
Article Title: Localization of Kv1.3 channels in presynaptic terminals of brainstem auditory neurons
Journal: The Journal of comparative neurology
doi: 10.1002/cne.22393

Figure Legend Snippet: Gradients of Kv1.3 immunoreactivity in sagittal and coronal sections of the MNTB. A. Sagittal section of MNTB immunostained for Kv 1.3. (scale bar, 20 μm). B and C. Coronal (B) and sagittal (C) sections were divided into 5 equal zones for quantification
Techniques Used:

Figure Legend Snippet: Electron microscopic immunogold labeling of Kv 1.3 in the MNTB of Wild-type and Kv 1.3 −/− mice. A and B. Examples of sections stained for Kv1.3 using 10 nm gold particles. Particles are localized primarily to pre-synaptic structures,
Techniques Used: Labeling, Mouse Assay, Staining

Figure Legend Snippet: Co-localization of Kv 1.3 with syntaxin, synaptophysin and synaptotagmin. Double immunofluorescence labeling of Kv1.3 with syntaxin (top panels A – E ), synaptophysin ( center panels F – J ) and synaptotagmin ( bottom panels K – O ). Kv 1.3
Techniques Used: Immunofluorescence, Labeling
2) Product Images from "The potassium channel Kv1.3 as a therapeutic target for immunocytoprotection after reperfusion"
Article Title: The potassium channel Kv1.3 as a therapeutic target for immunocytoprotection after reperfusion
Journal: Annals of Clinical and Translational Neurology
doi: 10.1002/acn3.51456

Figure Legend Snippet: Comparison of stroke severity in WT versus Kv1.3 −/− mice. (A) Infarct area and deficit score in 16‐week‐old WT ( n = 10) were compared to Kv1.3 −/− ( n = 14) male mice ( p
Techniques Used: Mouse Assay

Figure Legend Snippet: The Kv1.3 blocker PAP‐1 reduces infarction and improves neurological deficit in young and old WT female mice. (A) Infarct area and deficit score in vehicle ( n = 11) were compared to PAP‐1 (40 mg/kg; n = 15) treated 16‐week‐old female mice ( p = 0.007 for infarct, p = 0.016 for NES). (B) Infarct area and deficit score in vehicle ( n = 9) were compared to PAP‐1 (40 mg/kg; n = 9) treated 80‐week‐old female mice ( p = 0.032 for infarct, p = 0.003 for NES). Data are shown as whisker plots with data overlay. The boxes show mean ± SEM and the whiskers show confidence intervals.
Techniques Used: Mouse Assay, Whisker Assay

Figure Legend Snippet: Kv1.3 is expressed on microglia/macrophages and T cells in the infarct of an 80‐week‐old female mouse. (A) Sample immunofluorescence staining of 5‐ µ m thick paraffin sections from the 6‐mm slice of an 80‐week‐old female mouse on day 8 after tMCAO. (A) Kv1.3 staining colocalizes to Iba‐1 + cells. (B) Kv1.3 staining on smaller, CD3 + T cells (white arrowheads).
Techniques Used: Immunofluorescence, Staining

Figure Legend Snippet: PAP‐1 treatment and Kv1.3 deletion reduce Iba‐1 and CD3 staining in 80‐week‐old female mice. Serial paraffin sections (5 µ m thick) cut at 4 mm and the 6 mm from 80‐week‐old female mice were stained for Iba‐1 and CD3. (A) Percentage of Iba‐1‐positive pixels in the infarcted hemisphere. Vehicle‐treated WT ( n = 9), PAP‐1‐treated WT ( n = 9, p = 0.120 for 4‐mm section; p = 0.014 for 6‐mm section), and Kv1.3 −/− ( n = 18, p = 0.011 for 4‐mm section; p = 0.007 for 6‐mm section). (B) Percentage of CD3‐positive pixels in the infarcted hemisphere. Vehicle‐treated WT ( n = 9), PAP‐1‐treated WT ( n = 9, p = 0.049 for 4‐mm section; p = 0.027 for 6‐mm section), and Kv1.3 −/− ( n = 18, p
Techniques Used: Staining, Mouse Assay
3) Product Images from "Localization of Kv1.3 channels in presynaptic terminals of brainstem auditory neurons"
Article Title: Localization of Kv1.3 channels in presynaptic terminals of brainstem auditory neurons
Journal: The Journal of comparative neurology
doi: 10.1002/cne.22393

Figure Legend Snippet: Gradients of Kv1.3 immunoreactivity in sagittal and coronal sections of the MNTB. A. Sagittal section of MNTB immunostained for Kv 1.3. (scale bar, 20 μm). B and C. Coronal (B) and sagittal (C) sections were divided into 5 equal zones for quantification
Techniques Used:

Figure Legend Snippet: Electron microscopic immunogold labeling of Kv 1.3 in the MNTB of Wild-type and Kv 1.3 −/− mice. A and B. Examples of sections stained for Kv1.3 using 10 nm gold particles. Particles are localized primarily to pre-synaptic structures,
Techniques Used: Labeling, Mouse Assay, Staining

Figure Legend Snippet: Co-localization of Kv 1.3 with syntaxin, synaptophysin and synaptotagmin. Double immunofluorescence labeling of Kv1.3 with syntaxin (top panels A – E ), synaptophysin ( center panels F – J ) and synaptotagmin ( bottom panels K – O ). Kv 1.3
Techniques Used: Immunofluorescence, Labeling
4) Product Images from "KCNE4-dependent functional consequences of Kv1.3-related leukocyte physiology"
Article Title: KCNE4-dependent functional consequences of Kv1.3-related leukocyte physiology
Journal: Scientific Reports
doi: 10.1038/s41598-021-94015-9

Figure Legend Snippet: KCNE4 impaired Kv1.3 accumulation in the IS but did not disrupt IS formation. Human Jurkat T lymphocytes and human Raji B lymphocytes were used to generate cell conjugates. ( A – C ) Activated B-cells (10 µg/mL SEE toxin) were cocultured in the absence ( Ba – Bd ) or presence ( Ca – Cd ) of Jurkat cells, and confocal images were obtained. ( Aa – Ad ) Jurkat T-cells in the absence of B cells. Endogenous Kv1.3 (green), CD3 (marker of T-cells, red), and CD19 (marker of B-cells, blue) were detected. ( Ad , Bd , Cd ) merge panels. Note that triple colocalization (white) in Cd localizes Kv1.3 in the IS, as identified by CD3 staining ( Cb ). Bars are 20 µm. ( D ) Accumulation ratio of mGFP-Kv1.3 at the IS vs. KCNE4-mCherry total intensity (n = 40). ( E ) CD3 recruitment into the IS vs. KCNE4 intensity. The horizontal red line represents the threshold level (1.5) for Kv1.3 and CD3 accumulation in the IS. Values greater or less than 1.5 indicated positive or negative accumulation of proteins at the IS, respectively.
Techniques Used: Marker, Staining

Figure Legend Snippet: KCNE4 expression impairs Kv1.3 surface expression and inhibits Kv currents in Jurkat T cells. Confocal imaging of Jurkat T cells transfected with YFP, Kv1.3YFP, KCNE4CFP and KCNE4CFP with YFP-Kv1.3. Nuclei were stained with DAPI (blue). ( Aa – Ad ) Jurkat nontransfected cells (control). ( Ba – Bd ) YFP-transfected cells (YFP). ( Ca – Cd ) Kv1.3YFP transfected cells. ( Da – Dd ) KCNE4CFP transfected cells. ( Ea – Ed ) Kv1.3YFP and KCNE4CFP cotransfected cells. ( Aa , Ba , Ca , Da , Ea ) Kv1.3 in green. ( Ab , Bb , Cb , Db , Eb ) KCNE4 in red. ( Ac , Bc , Cc , Dc , Ec ) DAPI in blue. Merged yellow indicates colocalization between green and red ( Ad , Bd , Cd , Dd , Ed ). Scale bar: 5 µm. ( F ) FRET analysis of the Kv1.3-KCNE4 protein interaction by flow cytometry in Jurkat T lymphocytes. Values are mean ± SE, n = 5–7, *p
Techniques Used: Expressing, Imaging, Transfection, Staining, Flow Cytometry

Figure Legend Snippet: LPS-dependent activation of CY15 dendritic cells increases the abundance of Kv1.3 at the cell surface. CY15 cells were incubated in the presence (LPS) or the absence (control) of LPS for 24 h. Cells were first stained with WGA (membrane marker) and then immunolabeled against Kv1.3. ( A – D ) Control cells in the absence of LPS. ( E – H ) Cells treated with LPS. Green, Kv1.3; red, WGA; merged panels show colocalization between green and red. ( D , H ) Histogram of the pixel by pixel analysis of the section indicated by the arrow in ( C , G ), respectively. Bars represent 10 μm. ( I ) Mander's overlap coefficient (MOC) quantifying the degree of colocalization between Kv1.3 and membrane surface (WGA) staining. White bar, control; black bar, LPS. Values are mean ± SE of n > 30 cells. ***p
Techniques Used: Activation Assay, Incubation, Staining, Whole Genome Amplification, Marker, Immunolabeling

Figure Legend Snippet: KCNE4 overexpression modulates Kv1.3-related physiological events in Jurkat T lymphocytes. Jurkat T cells were electroporated with KCNE4CFP, and positively transfected cells were selected for specific assays. ( A ) Kv1.3 and KCNE4 expression in Jurkat cells. ( B ) Percentage of Jurkat T cell proliferation. Cells were serum starved overnight and cultured for an additional 24 h in the presence of FBS. The alamarBlue dye was used. *p
Techniques Used: Over Expression, Transfection, Expressing, Cell Culture

Figure Legend Snippet: Kv1.3 and KCNE4 are differentially expressed in leukocytes. The presence of Kv1.3 and KCNE4 expression was analyzed in human Jurkat T lymphocytes and mouse CY15 dendritic cells. ( A ) Kv1.3 and KCNE4 protein expression in leukocytes. HEK 293 cells were used as a negative control. Although Jurkat and CY15 dendritic cells shared Kv1.3 and KCNE4 expression, the abundance of KCNE4 in T cells was much lower and minimally detected by western blot. In addition, Kv1.5 was abundantly expressed in CY15 cells. Representative cropped blots, clearly separated by vertical white lines, are shown only for qualitative purposes. Voltage-dependent K + currents were elicited in Jurkat ( B ) and CY15 cells ( C ). Cells were held at -60 mV, and 250 ms pulse potentials were applied as indicated. ( D ) Representative confocal images of Kv1.3 ( Da and Dd , in green) and KCNE4 ( Db and De , in red) in Jurkat T lymphocytes ( Da – Dc ) and CY15 dendritic cells ( Dd – Df ). Scale bars: 10 µm. Given the limited expression of KCNE4 in T-cells, IPI was performed in Jurkat cells. ( E ) KCNE4 coimmunoprecipitated with Kv1.3 in dendritic cells. Lysates were immunoprecipitated against Kv1.3 (IP: Kv1.3) and immunoblotted (IB) against Kv1.3 and KCNE4. Upper panel: Kv1.3. Lower panel: KCNE4. SM: starting material. SN+: supernatant from the IP+. SN−: supernatant from the IP−. IP+: Immunoprecipitation in the presence of the anti-Kv1.3 antibody. IP−: Immunoprecipitated in the absence of the anti-Kv1.3 antibody. ( F ) Kv1.3 localized in lipid raft fractions from Jurkat T-cells. ( G ) Kv1.3 and KCNE4 did not localize in lipid rafts from CY15 dendritic cells. Lipid rafts were isolated, and low density (1) to high density (12) sucrose gradient fractions were analyzed by western blot. Flotilin indicated low-buoyancy lipid rafts, whereas clathrin identified nonfloating raft fractions.
Techniques Used: Expressing, Negative Control, Western Blot, Immunoprecipitation, Isolation

Figure Legend Snippet: LPS-dependent activation increases the Kv1.3/KCNE4 ratio in CY15 dendritic cells. Cells were treated for 24 h with LPS (100 ng/ml), and the protein expression of selected K + channel proteins was studied at 0, 6 and 24 h. ( A ) Confocal images of CY15 cells stained with Kv1.3 upon LPS treatment. Scale bars: 20 µm. ( B ) Representative voltage-dependent K+ currents elicited in CY15 cells treated with (LPS 24 h) or without (LPS 0 h) LPS during 24 h. Cells were held at -60 mV and 250 ms pulses to +60 mV were applied. ( C ) Peak current densitiy (pA/pF) of K + currents from CY15 cells in the absence (0 h) or the presence (24 h) of LPS. White bars, LPS 0 h (control); black bars, LPS 24 h. Values are the mean ± SE of 4–6 cells. *p
Techniques Used: Activation Assay, Expressing, Staining